Biblio

Export 2680 results:
Author Title Type [ Year(Desc)]
Filters: First Letter Of Keyword is A  [Clear All Filters]
2024
J. M. Chandler, Ye, W., Mi, X., Doty, E. G., and Johnston, J. A., “Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.”, J Alzheimers Dis, vol. 100, no. 2, pp. 563-578, 2024.
J. M. Chandler, Ye, W., Mi, X., Doty, E. G., and Johnston, J. A., “Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.”, J Alzheimers Dis, vol. 100, no. 2, pp. 563-578, 2024.
J. M. Chandler, Ye, W., Mi, X., Doty, E. G., and Johnston, J. A., “Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.”, J Alzheimers Dis, vol. 100, no. 2, pp. 563-578, 2024.
L. Zuo, Hu, Y., Dong, Y. H., Seet, R. Cs, Li, Z., Wang, Y., and Zhao, X., “Pre-existing dementia is associated with 2-3 folds risk for in-hospital mortality and complications after intracerebral hemorrhage stroke.”, J Alzheimers Dis, vol. 102, no. 2, pp. 338-346, 2024.
L. Zuo, Hu, Y., Dong, Y. H., Seet, R. Cs, Li, Z., Wang, Y., and Zhao, X., “Pre-existing dementia is associated with 2-3 folds risk for in-hospital mortality and complications after intracerebral hemorrhage stroke.”, J Alzheimers Dis, vol. 102, no. 2, pp. 338-346, 2024.
H. Kim, Le, B., Goshi, N., Zhu, K., Grodzki, A. Cristina, Lein, P. J., Zhao, M., and Seker, E., “Primary cortical cell tri-culture to study effects of amyloid-β on microglia function and neuroinflammatory response.”, J Alzheimers Dis, vol. 102, no. 3, pp. 730-741, 2024.
H. Kim, Le, B., Goshi, N., Zhu, K., Grodzki, A. Cristina, Lein, P. J., Zhao, M., and Seker, E., “Primary cortical cell tri-culture to study effects of amyloid-β on microglia function and neuroinflammatory response.”, J Alzheimers Dis, vol. 102, no. 3, pp. 730-741, 2024.
H. Kim, Le, B., Goshi, N., Zhu, K., Grodzki, A. Cristina, Lein, P. J., Zhao, M., and Seker, E., “Primary cortical cell tri-culture to study effects of amyloid-β on microglia function and neuroinflammatory response.”, J Alzheimers Dis, vol. 102, no. 3, pp. 730-741, 2024.
C. Cressot, Vrillon, A., Lilamand, M., Francisque, H., Méauzoone, A., Hourregue, C., Dumurgier, J., Marlinge, E., Paquet, C., and Cognat, E., “Psychosis in Neurodegenerative Dementias: A Systematic Comparative Review.”, J Alzheimers Dis, vol. 99, no. 1, pp. 85-99, 2024.
O. Snytnikova, Telegina, D., Savina, E., Tsentalovich, Y., and Kolosova, N., “Quantitative Metabolomic Analysis of the Rat Hippocampus: Effects of Age and of the Development of Alzheimer's Disease-Like Pathology.”, J Alzheimers Dis, vol. 99, no. s2, pp. S327-S344, 2024.
O. Snytnikova, Telegina, D., Savina, E., Tsentalovich, Y., and Kolosova, N., “Quantitative Metabolomic Analysis of the Rat Hippocampus: Effects of Age and of the Development of Alzheimer's Disease-Like Pathology.”, J Alzheimers Dis, vol. 99, no. s2, pp. S327-S344, 2024.
O. Snytnikova, Telegina, D., Savina, E., Tsentalovich, Y., and Kolosova, N., “Quantitative Metabolomic Analysis of the Rat Hippocampus: Effects of Age and of the Development of Alzheimer's Disease-Like Pathology.”, J Alzheimers Dis, vol. 99, no. s2, pp. S327-S344, 2024.
A. J. Espay, Herrup, K., Imbimbo, B. P., Kepp, K. P., and Daly, T., “Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.”, J Alzheimers Dis, vol. 99, no. 3, pp. 877-881, 2024.
A. J. Espay, Herrup, K., Imbimbo, B. P., Kepp, K. P., and Daly, T., “Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.”, J Alzheimers Dis, vol. 99, no. 3, pp. 877-881, 2024.
A. J. Espay, Herrup, K., Imbimbo, B. P., Kepp, K. P., and Daly, T., “Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.”, J Alzheimers Dis, vol. 99, no. 3, pp. 877-881, 2024.
A. J. Espay, Herrup, K., Imbimbo, B. P., Kepp, K. P., and Daly, T., “Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.”, J Alzheimers Dis, vol. 99, no. 3, pp. 877-881, 2024.
P. Sachdeva, Narayanan, K. Badri, Sinha, J. Kumar, Gupta, S., Ghosh, S., Singh, K. Kumar, Bhaskar, R., Almutary, A. G., Zothantluanga, J. H., Kotta, K. Kumar, Nelson, V. Kumar, Paiva-Santos, A. Cláudia, Abomughaid, M. Mohammad, Kamal, M., Iqbal, D., ALHarbi, M. Hamoud, ALMutairi, A. Aedh, Dewanjee, S., Nuli, M. Vamsi, Vippamakula, S., Jha, S. Kumar, Ojha, S., and Jha, N. Kumar, “Recent Advances in Drug Delivery Systems Targeting Insulin Signalling for the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 98, no. 4, pp. 1169-1179, 2024.
P. Sachdeva, Narayanan, K. Badri, Sinha, J. Kumar, Gupta, S., Ghosh, S., Singh, K. Kumar, Bhaskar, R., Almutary, A. G., Zothantluanga, J. H., Kotta, K. Kumar, Nelson, V. Kumar, Paiva-Santos, A. Cláudia, Abomughaid, M. Mohammad, Kamal, M., Iqbal, D., ALHarbi, M. Hamoud, ALMutairi, A. Aedh, Dewanjee, S., Nuli, M. Vamsi, Vippamakula, S., Jha, S. Kumar, Ojha, S., and Jha, N. Kumar, “Recent Advances in Drug Delivery Systems Targeting Insulin Signalling for the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 98, no. 4, pp. 1169-1179, 2024.
K. Ishii, Yamada, T., Hanaoka, K., Kaida, H., Kojita, Y., Kono, A., Hanada, K., Saigoh, K., Sakuta, S., Hashimoto, M., Kato, T., and Nakamura, A., “Regional differences in glucose metabolic decline and tau deposition in the Alzheimer's continuum brain.”, J Alzheimers Dis, vol. 102, no. 1, pp. 228-236, 2024.
K. Ishii, Yamada, T., Hanaoka, K., Kaida, H., Kojita, Y., Kono, A., Hanada, K., Saigoh, K., Sakuta, S., Hashimoto, M., Kato, T., and Nakamura, A., “Regional differences in glucose metabolic decline and tau deposition in the Alzheimer's continuum brain.”, J Alzheimers Dis, vol. 102, no. 1, pp. 228-236, 2024.
K. Ishii, Yamada, T., Hanaoka, K., Kaida, H., Kojita, Y., Kono, A., Hanada, K., Saigoh, K., Sakuta, S., Hashimoto, M., Kato, T., and Nakamura, A., “Regional differences in glucose metabolic decline and tau deposition in the Alzheimer's continuum brain.”, J Alzheimers Dis, vol. 102, no. 1, pp. 228-236, 2024.
K. Ishii, Yamada, T., Hanaoka, K., Kaida, H., Kojita, Y., Kono, A., Hanada, K., Saigoh, K., Sakuta, S., Hashimoto, M., Kato, T., and Nakamura, A., “Regional differences in glucose metabolic decline and tau deposition in the Alzheimer's continuum brain.”, J Alzheimers Dis, vol. 102, no. 1, pp. 228-236, 2024.
H. Stevens Smith, Robinson, J. O., Levchenko, A., Pereira, S., Pascual, B., Bradbury, K., Arbones, V., Fong, J., Shulman, J. M., McGuire, A. L., and Masdeu, J., “Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1261-1274, 2024.
H. Stevens Smith, Robinson, J. O., Levchenko, A., Pereira, S., Pascual, B., Bradbury, K., Arbones, V., Fong, J., Shulman, J. M., McGuire, A. L., and Masdeu, J., “Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1261-1274, 2024.
H. Stevens Smith, Robinson, J. O., Levchenko, A., Pereira, S., Pascual, B., Bradbury, K., Arbones, V., Fong, J., Shulman, J. M., McGuire, A. L., and Masdeu, J., “Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1261-1274, 2024.

Pages